PPARA and metabolic syndrome: Despite accumulating evidence of the residual cardiovascular risks resulting from elevated TGs and lower HDL-C levels, low potent synthetic PPARα agonists (fibrates) have not shown enough evidence to reduce the definitive mortality rate when combined with statin treatment, despite an improvement in dyslipidemia.